Tuesday, January 10, 2023 2:45:24 PM
MF had said in the past he will sell Bucci on the open market in the event FDA denies.
Anyone know what that looks like? Id assume will not be able to sell within the US. Focus on 2nd & 3rd world countries for off label use?
Will this help the share price at all if they can maintain revenues via this method? Or does the SP tank?
Anyone know what that looks like? Id assume will not be able to sell within the US. Focus on 2nd & 3rd world countries for off label use?
Will this help the share price at all if they can maintain revenues via this method? Or does the SP tank?
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
